22CT015: CART 19-22 co-administration

Contact

If you are interested in participating in the study or want to learn more, please get in touch.

This study is now recruiting. Learn more about enrolling here.

Description

CAR T cell therapy has shifted the treatment landscape for pediatric and young adult patients with advanced B-cell leukemias. This study aims to treat patients with relapsed disease by administering two CART cell products, huCART19 and CART22-65s. The study will determine the safety and efficacy and usefulness of administering two CAR T cell products in patients with advanced B-cell leukemias. This is a Phase 1/2b trial for the treatment of patients with either advanced or refractory B cell Acute Lymphoblastic Leukemia or B-lineage lymphoblastic lymphoma. Possible procedures include medical record review, apheresis, huCART19 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. Overall, approximately 93 subjects will be enrolled on this clinical trial.

Eligibility and criteria

IRB Number:

22-020640

Clinical trial phase:

Phase I

Phase II

Official title:

Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered with Humanized Anti-CD19 CAR T cells (huCART19) in Children and Young Adults with Relapsed or Refractory B-ALL - (NCT05674175)

What to expect

This study is open to enrollment and currently accepting new patients.

Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.

Find a research study

Innovation and your child

Find research studies